The biotech and pharma industries are rapidly evolving, with mergers and acquisitions driving innovation and growth. As market demands shift, these deals reshape strategies, bolster R&D, and bring groundbreaking therapies to healthcare.

With over 35 years of experience, Stephen Sands has guided high-impact transactions that have shaped the biotech and pharma landscape. In this episode, Janice Bourque speaks with Stephen about his journey from bioengineer to healthcare M&A leader. They examine the forces that drive today’s major deals, from global expansion to complex valuation challenges, and the strategies that ensure success in a competitive market.

Topics Include:

• Key trends and strategies in biotech/pharma M&A
• Challenges in valuing early-stage biotech companies
• Pharma’s evolving role in funding and scaling biotech innovations
• Future outlook for healthcare partnerships and acquisitions
• Stephen’s insights on the future of healthcare M&A
• And other topics…

Stephen Sands is a Senior Advisor in Lazard’s Global Healthcare Group with a distinguished career in healthcare M&A. Known for his expertise in biotech and pharma, Stephen has led some of the industry’s most transformative transactions, helping to drive strategic growth and innovation in the healthcare sector.